GlassScriptPhysician profile
Jenny Joo
NPI 1821411570
$10,428.78
in general payments reported to CMS, 2019-2025
62 companies · $7,836 in 2025
The $7,836 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,592 · 2025: $7,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,428.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $664.13 | 2024-2025 | |
| Janssen Biotech, INC. | $647.93 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Eisai INC. | $541.08 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.45 | 2024-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $483.43 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $468.58 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $446.86 | 2024-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Novartis Pharmaceuticals Corporation | $440.26 | 2024-2025 | |
| Incyte Corporation | $417.52 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $386.44 | 2024-2025 | Opdivo, Opdualag |
| Karyopharm Therapeutics INC. | $377.69 | 2024-2025 | Xpovio |
| Pfizer INC. | $343.45 | 2024-2025 | |
| Sobi, INC | $297.66 | 2024-2025 | |
| Daiichi Sankyo INC. | $284.64 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Glaxosmithkline, LLC. | $283.60 | 2025 | Ojjaara, Blenrep, Jemperli |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $268.53 | 2024-2025 | Verzenio, Jaypirca |
| Beone Medicines USA, INC. | $229.34 | 2025 | Tevimbra, Brukinsa |
| Puma Biotechnology, INC. | $229.01 | 2024-2025 | |
| Genentech USA, INC. | $212.00 | 2025 | Tecentriq, Phesgo, Itovebi |
| Celgene Corporation | $195.69 | 2024-2025 | Reblozyl, Opdualag, Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.67 | 2025 | |
| Genzyme Corporation | $148.23 | 2024-2025 | |
| Genmab U.S., INC. | $140.92 | 2024-2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $131.50 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $127.64 | 2024-2025 | Somatuline Depot, Onivyde |
| Pharmacosmos Therapeutics INC. | $113.75 | 2025 | Monoferric |
| Exelixis INC. | $110.08 | 2024-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $109.08 | 2025 | |
| Adc Therapeutics America, INC. | $108.98 | 2025 | |
| Agios Pharmaceuticals, INC. | $103.73 | 2024-2025 | Pyrukynd |
| Caris Mpi, INC. | $100.69 | 2025 | Mi Cancer Seek |
| Recordati_rare_diseases_inc. | $93.58 | 2025 | Enjaymo |
| Astellas Pharma US INC | $86.29 | 2025 | Vyloy, Xtandi |
| Gilead Sciences, INC. | $84.29 | 2025 | Trodelvy |
| Beigene USA, INC. | $77.04 | 2024-2025 | Brukinsa |
| Array Biopharma INC | $73.27 | 2025 | Xalkori, Lorbrena, Braftovi |
| Coherus Oncology, INC. | $68.64 | 2024-2025 | Loqtorzi |
| Deciphera Pharmaceuticals INC. | $66.89 | 2025 | Qinlock, Romvimza |
| Pharmaessentia USA Corporation | $66.26 | 2025 | Besremi |
| Iovance Biotherapeutics, INC. | $62.90 | 2025 | Amtagvi |
| Syndax Pharmaceuticals, INC. | $62.88 | 2025 | |
| Dendreon Pharmaceuticals LLC | $60.45 | 2025 | Provenge |
| Legend Biotech USA INC. | $57.30 | 2024-2025 | Carvykti |
| Tersera Therapeutics LLC | $55.33 | 2025 | Xermelo |
| Servier Pharmaceuticals LLC | $50.46 | 2025 | |
| Blueprint Medicines Corporation | $31.44 | 2024 | Ayvakit |
| Geron Corporation | $30.45 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $30.05 | 2025 | Givlaari |
| Immunocore Limited | $29.55 | 2024 | Kimmtrak |
| Invivyd INC | $28.48 | 2025 | Pemgarda |
| Adaptive Biotechnologies Corporation | $26.69 | 2025 | Clonoseq |
| Nuvation Bio INC. | $26.64 | 2025 | Ibtrozi |
| Regeneron Healthcare Solutions, INC. | $25.65 | 2024 | Libtayo |
| Stemline Therapeutics INC. | $25.35 | 2024 | Orserdu |
| Accord Healthcare, INC. | $24.92 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.19 | 2024 | Ultomiris |
| Emd Serono, INC. | $20.80 | 2025 | |
| Rigel Pharmaceuticals, INC. | $19.83 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Novocure INC. | $19.00 | 2025 | Optune Lua (Novottf-200t) |
| Taiho Oncology, INC. | $16.97 | 2025 | |
| Kyowa Kirin, INC. | $15.85 | 2025 | |
| Apellis Pharmaceuticals, INC. | $15.78 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Joo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.